for people ages 18-75 (full criteria)
at UC Davis UCSF
study started
estimated completion
Vijay Balasubramanian, MD(ucsf)Roblee Allen, MD(ucdavis)



This study is an international, multi-center, open-label study designed to provide oral treprostinil (UT-15C) to eligible subjects with pulmonary arterial hypertension who have completed the TDE-PH-310 study. The purpose of this study is to assess the long-term safety of UT-15C and to assess the effects of long-term treatment with UT-15C on exercise capacity.

Official Title

Open-Label Extension Study of UT-15C in Subjects With Pulmonary Arterial Hypertension- A Long-Term Follow-Up to Protocol TDE-PH-310


Pulmonary Arterial Hypertension PAH PH FREEDOM 6 minute walk test treprostinil open label Familial Primary Pulmonary Hypertension Hypertension UT-15C (treprostinil diethanolamine)


You can join if…

Open to people ages 18-75

  • Participated in United Therapeutics Study TDE-PH-310

You CAN'T join if...

  • Premature discontinuation of United Therapeutics Study TDE-PH-310 due to reasons other than clinical worsening


  • University of California, San Francisco-Fresno accepting new patients
    Fresno California 93701 United States
  • University of California-Davis Medical Group, Advanced Lung Disease/Transplant Program accepting new patients
    Sacramento California 95817 United States
  • Cedars-Sinai Medical Center accepting new patients
    Los Angeles California 90211 United States

Lead Scientists

  • Vijay Balasubramanian, MD (ucsf)
    Vijay Balasubramanian, M.D. Clinical Professor of Medicine, UCSF Medical Director of Pulmonary Hypertension-Community Regional Medical Center Vijay Balasubramanian, M.D., specializes in pulmonary disease. He is board certified in Internal Medicine. His residency and fellowship training were completed at the Medical College of Wisconsin.
  • Roblee Allen, MD (ucdavis)
    Professor, Pulmonary, Critical Care, and Sleep Medicine. Authored (or co-authored) 39 research publications


accepting new patients
Start Date
Completion Date
United Therapeutics
Phase 3
Study Type
Last Updated